January 13, 2022 PANTHERx® Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev®...

Read the Official PANTHERx Press Release. PANTHERx Rare has again been recognized as the winner of the annual, national Specialty Pharmacy Patient Choice Award™. “The results of the Managed Markets Insights & Technology Zitter Health Insights (MMIT...

Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy announces that it has been selected by ChemoCentryx as a limited distribution partner for new drug TAVNEOS (avacopan). TAVNEOS, an orally administered selective complement 5a receptor inhibitor,...

Read the Official PANTHERx Press Release. PANTHERx Rare announced today that it was selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as the exclusive U.S. pharmacy distribution partner for EXSERVAN™ (riluzole). The drug, an oral film formulation...

Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE™ (setmelanotide). The drug was approved by the U.S. Food...

PANTHERx is proud to join the Centene family of companies. Through this transaction, we are reaffirming our relentless commitment to transforming lives and removing barriers for individuals living with complex and rare diseases. Read the official press...